Neuropathogenesis of Congenital Cytomegalovirus Infection: Disease Mechanisms and Prospects for Intervention

Maxim C.-J. Cheeran, James R. Lokensgard, and Mark R. Schleiss

INTRODUCTION

Congenital cytomegalovirus (CMV) infection is a major public health concern. CMV causes serious neurodevelopmental sequelae, including mental retardation, cerebral palsy, and sensorineural hearing loss (SNHL). Even with antiviral therapy, these injuries are often irreversible. The pathogenesis of injury to the developing fetal central nervous system (CNS) is unknown. This review focuses on potential pathogenic mechanisms by which CMV injures the CNS. This includes analysis of the cell types infected with CMV, the pattern of injury to the fetal brain, and the long-term neurodevelopmental impact. Multiple mechanisms are proposed to play a potential role(s) in CNS injury. These include the following: CMV acting as a “teratogen,” disrupting normal cellular differentiation and

| INTRODUCTION                                                                                                                                   |
| Background and Epidemiology of Congenital CMV Infection                                  |
| Magnitude of the problem                                                                                                                     |
| Prevalence and risk factors                                                                                                                   |
| PATHOLOGY                                                                                                                                            |
| Brain Structural Anomalies, Imaging Abnormalities, and Clinical Correlation              |
| Auditory Abnormalities                                                                                                                        |
| Pathogenesis of CMV Labyrinthitis                                                        |
| Cell Types Infected                                                                       |
| PATHOGENESIS                                                                                                                                         |
| Developmental Biology Paradigm: Is CMV a Teratogen?                                       |
| Apoptosis and Cell Cycle Changes                                                         |
| Neural Stem Cells in CMV Infection                                                       |
| Developmental Susceptibility to CMV Infection                                             |
| Neuroinflammatory Processes                                                               |
| Ontogeny of the immune response                                                          |
| Altered immune responses of the fetus may increase susceptibility                       |
| Cytokine-mediated damage                                                                  |
| Placental Insufficiency: Vascular Damage, Hypoxia, and Altered Permeability              |
| ANIMAL MODELS                                                                                                                                   |
| Murine Model                                                                              |
| Guinea Pig Model                                                                         |
| Rhesus Macaque Model                                                                     |
| Other Animal CMVs                                                                        |
| INTERVENTIONS                                                                             |
| Antiviral Drugs                                                                          |
| Ganciclovir                                                                               |
| Valganciclovir                                                                           |
| Foscarnet                                                                                |
| Cidofovir                                                                                |
| CMV Immune Globulin                                                                      |
| Vaccines                                                                                 |
| Live, attenuated CMV vaccines                                                            |
| Subunit CMV vaccines                                                                      |
| (i) Adjuvanted protein vaccines                                                           |
| (ii) DNA vaccines                                                                        |
| (iii) Vectored vaccines                                                                  |
| Preclinical vaccine approaches                                                            |
| Validation of vaccines for congenital CMV in animal models                                |
| SUMMARY AND PERSPECTIVES                                                                                                                       |
| ACKNOWLEDGMENTS                                                                          |
| REFERENCES                                                                               |
morpheogenesis pathways; the impact on apoptosis and anti-apoptotic mechanisms; the role of neural stem cells; the critical developmental windows of susceptibility; the role of the inflammatory processes in potentiating CNS injury; and the potential pathogenic impact of CMV on the endovascular system. Insights into the pathogenesis of CNS injury caused by CMV have been obtained from studies in primate, mouse, and guinea pig models. An improved understanding of the pathogenesis of CNS injury should help direct translational vaccine and antiviral interventions that can be applied to the management of infected infants.

**Background and Epidemiology of Congenital CMV Infection**

**Magnitude of the problem.** Congenital CMV infection is the major cause of birth defects and childhood disorders in the United States. It is estimated that about 40,000 children (0.2 to 2% of all deliveries) are born with CMV, resulting in about 400 fatal cases each year (44). Only 10 to 15% of children with congenital CMV infection exhibit clinical signs at birth, although even children who appear asymptomatic at birth are at risk for neurodevelopmental sequelae (34). Most children (60 to 90%) with symptomatic infection, and 10 to 15% of those with asymptomatic infection, develop one or more long-term neurological sequelae, such as mental retardation, psychomotor retardation, SNHL, and ophthalmologic abnormalities (12, 35, 91, 142). Current estimates indicate that approximately 8,000 children are affected each year with some neurological sequelae related to in utero CMV infection. This incidence is far greater than that of better-known childhood disorders, such as Down syndrome (4,000/year), fetal alcohol syndrome (5,000/year), or spinal bifida (3,500/year), making congenital CMV infection the most common cause of birth defects and childhood disorders in the United States (44). Considering the public health significance of CMV-related long-term neurological disabilities, it is surprising that more attention is not paid to understanding the neuropathogenesis of congenital CMV infection. This review addresses current concepts regarding the epidemiology, pathogenic mechanisms, and intervention strategies being considered for this important clinical problem.

**Prevalence and risk factors.** CMV infection is ubiquitous in the human population, and most individuals are eventually infected. Human CMV is a large DNA virus belonging to the family Herpesviridae. Like all herpesviruses, CMV establishes a lifelong latency in the host, with periodic reactivations (180). The overall age-adjusted prevalence of CMV in the United States is about 60%. Although only 0.5 to 1% of children acquire CMV in utero, 40% acquire the infection within the first decade of life. Seroprevalence increases to >80% by the age of 60 (132, 255). Seroprevalence varies among different socioeconomic and ethnic groups and increases among individuals with proximity to infected children or working in childcare facilities (83, 193, 255). It is quite well documented that the risk of congenital CMV is the greatest from a primary infection (i.e., infection in a seronegative individual) of the mother during pregnancy. Transplacental transmission of virus occurs in about one-third of mothers with primary CMV infection (39, 85, 132), and approximately one-half of these infections in utero result in a symptomatic clinical syndrome (6). Epidemiological data suggest that the timing of acquisition of primary infection relative to the establishment of pregnancy is an important factor in establishing the risk to the fetus for in utero transmission (222). Although women who are CMV seropositive preconception are less likely to give birth to an infant with congenital CMV than women who have a primary CMV infection during pregnancy, transplacental transmission with its attendant sequelae still occurs in this setting (fetal infection rate of 1.4% [132]). Transmission in this setting appears to be related to reinfection of seropositive women with new strains of CMV (34, 39). Maternal nonprimary infections account for the major disease burden associated with congenital CMV. It has recently become appreciated that congenitally infected infants born to women with preconception immunity are at substantial risk for long-term neurological sequelae (39, 81, 85, 225). In a study of 300 children with confirmed congenital CMV, Ross et al. observed that in congenitally infected babies born to seropositive women, the incidence of hearing loss and other congenital damage was similar to that observed in congenital infection occurring in the setting of primary gestational infection (226). Better data are needed regarding the incidence of congenital CMV infection, since congenital infection rates have been examined in relatively few populations. The advent of routine newborn screening for congenital CMV could provide a clearer picture of the overall disease burden (224).

Seronegative women of child-bearing age (15 to 44 years of age) undergoing primary infection have the highest risk of transplacental transmission of CMV. For a pregnant woman, exposure to CMV-infected children, often her own children who have acquired infection in group day care, is a common primary source of infection (3). Young children shed virus at mucosal surfaces for prolonged periods of time. It is well documented that both symptomatic and asymptomatic infants excrete virus in the urine and saliva for many years after birth. Virus shedding in the urine is often detectable until ~10 years of age, with the mean shedding interval being ~4 years (189). In addition, between 15 to 70% of children acquire CMV infection in group day care settings and continue to shed the virus for 6 to 48 months (mean = 18 months) after primary infection (3). Because of chronic nature of CMV infection in young children, they serve as an excellent reservoir for the virus. Pregnant women who have provided care to young children a year before delivery have an increased risk for maternal CMV infection, and this situation increases the risk of transmission of the virus to the fetus (83). CMV infection is readily transmitted to the pregnant mother at mucosal surfaces via infected urine, saliva, or other bodily fluids, but respiratory or aerosol transmission is not common (169). There is also potential for fomite-mediated transmission of CMV (238). Simple hygienic practices such as hand washing can dramatically reduce infection rates in pregnant mothers (44).

Sexual activity is an important mode of virus transmission in women of reproductive age (256). CMV can readily be isolated from the genital tracts of both sexes (42). In young women, a risk factor for congenital CMV infection is the recent onset of sexual activity (83). This study noted that early sexual debut (<16 years), a history of multiple sexual partners, and a history of sexually transmitted infections were not risk factors for transplacental transmission (83), possibly because these activities are associated with seroconversion rates early after the
onset of sexual activity but prior to the onset of child-bearing. Since a longer interval between primary infection and pregnancy allows women sufficient time to develop high-avidity antibody to CMV, this in turn may result in a decreased risk of transplacental transmission (248, 253).

In utero infection is believed to be due to maternal viremia with attendant hematogenous spread to the fetus. The rate of materno-fetal transmission is influenced by numerous factors, including trimester of exposure, maternal age, CMV serostatus, character of maternal immunity, and viral loads. The risk of fetal transmission appears to increase with gestational age, but neurological outcomes are more severe when infection occurs during the first trimester (6, 184, 196, 198). However, viral transmission can occur during the entire gestation period, and neurological outcomes may still be seen from infections acquired in late gestation (198, 254). Young maternal age increases the risk for congenital CMV infection. Women who are 20 years of age or less at delivery have a three-times-greater likelihood of delivering an infected infant than older women (42, 84). This increase in age-related risk may be due to a greater probability of primary exposure to the virus in this age group or may be a combination of age-related biological effects on CMV replication (83, 85).

Although is generally accepted that preconception immunity to CMV provides a substantial protective effect against materno-fetal transmission, there have been reports suggesting that maternal antibody titers alone may not be a good indicator of fetal protection (34, 39, 85, 224). The presence of maternal antibodies has been shown to be associated with a decreased incidence of CMV and with improved neurological outcomes in the setting of congenital infection (71, 83). Paradoxically, immunoglobulin G (IgG) antibodies to the viral glycoprotein B (gB) after primary infection are significantly increased in maternal and newborn delivery sera for infants who develop hearing loss (33, 38), suggesting a possible increased exposure to viral antigen. It appears that the qualitative aspects of the antibody response (i.e., presence of neutralizing, high-avidity antibodies) are a critical indicator of fetal protection (33, 148). Antibody-mediated protection against fetal transmission is not absolute. As already noted, the failure of preconception immunity to provide complete protection against congenital CMV infection may be strongly related to reinfection with different strains of CMV with new antibody specificities (39). This observation complicates the development of CMV vaccines based on single proteins such as envelope glycoproteins, since immunity to glycoproteins from one strain may not protect against reinfection with another strain with a different protein-coding sequence in key neutralizing epitopes.

Maternal antibodies are known to effectively cross the maternal-fetal interface, conferring passive immunity to infections. However, antibody may actually facilitate transmission of CMV across the placenta. CMV has been shown to utilize maternal IgG to cross the placenta via transcytosis as IgG-virion complexes utilizing the neonatal Fc receptor (FcRn) that is expressed on the surface of syncytiotrophoblasts (16). It is postulated that IgG-virion complexes formed of high-avidity neutralizing antibodies may be quickly neutralized by villus core macrophages on the fetal side, whereas low-avidity antibody complexes allow virus to escape the macrophages and infect the fetus (161). Thus, in this model, the timing of infection relative to the establishment of pregnancy and the antibody avidity to CMV are critical determinants of protection. Low-avidity antibodies persist for up to 20 weeks after a primary infection (148), and this may be a window of high risk. Once infection of the fetus is established, it is not clear what role antibody plays in ameliorating the risk of injury. In one study, passive administration of CMV antibodies in the postnatal period did not alter the development of certain neurological sequelae, including progressive hearing loss, in the setting of congenital CMV infection (37). The chief benefit of antibody may be its effect on prevention of transplacental transmission. However, there is recent evidence that CMV immune globulin may be therapeutic for a fetus already infected in utero. Therapeutic administration of high-titer CMV Ig during pregnancy in women with evidence of primary infection has been shown in uncontrolled trials to decrease transmission to the fetus, improve ultrasonic abnormalities in the developing fetus, and improve overall placental health (5, 184). Controlled studies are required to confirm these observations and to further examine the potential benefits of immune globulin both in utero and in the newborn.

CMV infection acquired in utero has the potential to result in considerable neurodevelopmental morbidity. Remarkably, hearing loss due to congenital CMV infection can progress through early childhood even when it is clinically unapparent at birth. While it is difficult to accurately predict the severity of congenital CMV infection, several predictive criteria have been suggested (149). Serial ultrasonograms or cranial computed tomography scans are useful to detect overt pathological alterations in the fetal brains of symptomatic children and can accurately predict development of cognitive and motor deficiencies (11, 36, 188). Recently, head ultrasound has also been shown to be of value in predicting the magnitude of injury in the newborn CNS in the setting of congenital infection (11). The lack of detectable lesions in asymptomatic newborns may not preclude them from developing hearing loss later in life (11). Lazzarotto et al. suggested a three-pronged approach for the diagnosis of and prediction of outcomes in congenital CMV infection (149): (i) screening for maternal antibodies to determine primary infection in the mother, including assessment of an avidity index of CMV IgG; (ii) prenatal ultrasound to examine for the presence of fetal abnormalities; and finally (iii) amniocentesis with quantitative PCR analysis for CMV-specific DNA in the amniotic fluid. Thus far, quantitative analysis of viral load has proved to be the best predictor for neurological damage in congenital CMV infection (149). Levels of greater than 1,000 genome copy equivalents in the amniotic fluid were 100% predictive of fetal transmission, and higher loads (>5,000 copies) were predictive of symptomatic infections (149). The increase in viral genomes in the amniotic fluid may reflect the magnitude of the viral load in the fetus, manifest as viral replication in the fetal kidney and excretion via the fetal urine.

**PATHOLOGY**

Among the primary clinical manifestations associated with congenital CMV infection, the most devastating are those involving the developing CNS, since in contrast to other end-organ injury, CNS injury is generally believed to...
be irreversible. The most commonly observed symptoms of CMV infection at birth are intrauterine growth retardation, purpura, jaundice, hepatosplenomegaly, microencephaly, hearing impairment, and thrombocytopenia (11, 142). While clinical signs due to abnormalities of the reticuloendothelial system (such as anemia, hepatosplenomegaly, and jaundice) are transient, neurological deficits either are evident at birth and typically persist for life or tend to become evident (as SNHL) in early childhood.

**Brain Structural Anomalies, Imaging Abnormalities, and Clinical Correlation**

The earliest demonstrated structural brain abnormalities have been observed through fetal imaging studies, as early as 28 weeks of gestation, using either magnetic resonance images or ultrasonograms. T2- and T1-weighted magnetic resonance imaging scans of CMV-infected fetal brains show white matter abnormalities reflective of acute responses, such as loss of intermediate zone layer, focal necrosis, and hemorrhaging. More commonly seen are chronic lesions due to infection, which include ventricular dilatation, white matter gliosis, atrophy (volume loss), parenchymal cysts, ependymal cysts, calcifications, and cortical malformations (most notably polymicrogyria [22]). Fetal sonographic analyses at between 22 and 37 weeks of gestation also detect structural changes in the brain. Transvaginal ultrasonograms show different patterns of abnormal periventricular hyper/hy pochogenicity, ventricular adhesions, cystic formation around the ventricles, ependymal protrusions, normal sulcations, and hypoplastic corpus callosum (162). Periventricular cysts develop during the second trimester, cerebellar lesions probably are the result of fetal infection before 18 weeks of gestation, and abnormal sulcations probably are due to injury between 18 and 24 weeks (162). Fetal imaging studies are useful in determining the time and extent of fetal infection, and these findings may in turn help prognosticate neurological outcomes (23).

Neonatal and postnatal imaging of children with symptomatic CMV is almost always associated with structural brain abnormalities similar to those observed in the infected fetus (Fig. 1). The most frequent of these is the presence of intracranial calcifications (50%). Computed tomography scans also show other abnormal changes, such as ventriculomegaly, white matter changes, polymicrogyria, cysts, structural abnormalities, and extensive encephalopathy (36, 188). Other abnormalities observed in the spectrum of neuroimaging/pathological abnormalities include lissencephaly, porencephaly, and schizencephaly (Fig. 1C). Abnormal results from cranial ultrasonograms (showing periventricular or parenchymal calcifications, increased ventricular size, and cerebellar lesions) performed during the first week of life are helpful for symptomatic children in predicting development of some neurological deficit in life (11). Typically, asymptomatic children do not show extensive calcifications or ventriculomegaly (283). The presence of distinct but subtle patterns of white matter lesions with or without polymicrogyria and in combination with anterior temporal lobe cysts is suggestive of CMV infection (274). At least one case of asymptomatic white matter magnetic resonance lesions has been reported in an infant who also developed SNHL (104). The extent to which these white matter lesions seen in magnetic resonance imaging correlate with development of hearing loss or other neurological syndromes is yet to be determined.

**Auditory Abnormalities**

CMV is currently the leading cause of nonhereditary SNHL in children (192). CMV infection is associated with 10 to 60% of all SNHL in children. CMV-related SNHL either can be manifested at birth or may be progressive in nature, with deterioration in hearing potentially occurring over the first several years of life. Numerous epidemiological studies have linked congenital CMV infection to the development of SNHL (196), but the viral and/or host inflammatory mechanisms involved in the pathogenesis of auditory dysfunction remain unclear. In the era of routine immunization for Haemophilus
The frequency of hearing loss in children due to CMV infection is between 0.2 and 1.3/1,000 live births (196). The risk of SNHL is higher among children with symptomatic CMV infections (30 to 65%) than among those with asymptomatic congenital infection (7 to 15%). Hearing loss is often the only sequela identified in the latter group (61, 115, 283). Various studies define SNHL in children differently, complicating the estimation of the full magnitude of the effect of CMV on the incidence of hearing disabilities. One useful definition, proposed by Fowler et al., defined normal hearing in a child as perception of sounds that range between 0 and 20 dB at frequencies of between 20 and 20,000 Hz. SNHL was defined as an air-bone gap of less than 10 dB and greater than 21-dB thresholds for the affected frequencies (81, 82). Another aspect of CMV-related SNHL, which has only recently been appreciated, is that the rate of hearing loss increases with age. Hearing loss of less than 20-dB threshold was seen in 5.3% of congenitally infected children at birth (among 338), which increased to 6.5% at 3 months, 8.4% by 1 year, and 15% by 6 years of age. Although virtually all states in the United States mandate universal newborn hearing screening, such screening will fail to identify the majority of cases of CMV-associated SNHL, due to the large proportion of affected children who have hearing loss that has its onset in later childhood or progressively increases over time (81).

The progressive nature of SNHL suggests that there may be a chronic infection in the CNS or endolabyrinth that continues to be active throughout early childhood. Alternatively, it may reflect an alteration in developmental gene expression resulting from in utero infection, although the absence of structural anomalies in the endolabyrinth argues against this hypothesis. Viral load appears to correlate with the risk of SNHL. Increased levels and longer duration of urinary excretion of CMV in both symptomatic and asymptomatic congenitally infected children, early in life, are associated with development of hearing loss. Infants with less than 5,000 PFU/ml infectious virus in the urine or less than 10,000 genome copies/ml in peripheral blood may have a lower likelihood of developing progressive hearing loss (13, 35). Furthermore, children with SNHL or progressive SNHL continue to excrete virus in the urine for >4 years, suggesting that the risk of SNHL is related to ongoing active viral replication and high viral burden in congenitally infected children (189).

**Pathogenesis of CMV Labyrinthitis**

CMV-induced hearing loss is believed to be caused by virus-induced labyrinthitis (259). Inner ear histology from congenitally infected infants shows damage to structures including the vestibular endolymphatic system and the vestibular organs (saccule and utricle) and collapse of the saccular membrane (62). Damage is restricted to the endolymphatic structures, with minor involvement of the cochlea, manifest mainly as hydrops at the basal turn (62, 217). Inclusion-bearing cells are seen in the epithelium of the endolymphatic sac and are positive for CMV antigens (17, 62). It is postulated that CMV enters the endolymph via the stria vascularis (258), and, compatible with this hypothesis, viral DNA can be detected in the perilymph by quantitative PCR analysis (26, 261). To better understand the damage caused by CMV infection of the inner ear, experimental animal models have been extensively used. Elsewhere in this review, the pathogenesis of CMV-induced labyrinthitis in animal models will be discussed.

**Cell Types Infected**

The neurotropism of CMV is evident from the predominance of CNS abnormalities observed in the setting of symptomatic congenital infection. However, although the brain is a major target of end-organ damage in this setting, the precise cellular targets of infection remain incompletely characterized. Inclusion bodies are detected during postmortem histological analysis of the brain (201, 236), but few or no histological data identifying the different cell types infected during congenital CMV are available. Most of what we know today about susceptibility of brain cells to CMV infection has been afforded by experiments performed on cultured human brain cells and from animal models of brain infection. In primary human cell culture systems or brain-derived cell lines it has been shown that practically all cell types in the brain have some degree of susceptibility to CMV infection. Brain microvascular endothelial cells (EC) (77, 146, 208), astrocytes (157), neuronal cells (208), oligodendroglial cells (253), microglia/macrophages (213, 239), and neural progenitor/stem cells (51, 167) have a propensity for CMV infection. However, these different cell types vary in their ability to support a complete viral replication cycle, which in turn is largely controlled by the transcription factor milieu within the cell during infection.

Astrocytes, the major cell type, constituting about 70% of the brain, support CMV replication. Primary human fetal astrocyte cultures show productive and cytopathic viral replication, with immediate-early (IE) gene expression and early gene promoter upregulation. Titers of infectious virus in cell supernatants show an increase of 2 to 3 log units over a course of 5 days (157, 168). Different astroglial cell lines support CMV replication to different levels. Some cell lines, such as BHRA, HS-63, and U373-MG, are permissive for complete viral replication, while in some (glioblastoma and T98G cells) replication is aborted at the IE stage (208).

Astrocytes, in association with brain microvasculature EC (BMVEC), form the blood-brain barrier, a structure that maintains the highly regulated solute and cellular microenvironment in the CNS (1). EC derived from the microvasculature also support productive CMV replication (77, 208). Lytic viral replication is supported by BMVEC, whereas, in contrast to BMVEC, EC from the aorta afford persistent viral replication for up to 30 days without cell lysis (77). Three viral genes have been identified as being critical for CMV infection in EC: UL128, UL130, and UL131A. These genes have a striking tendency to mutate during cell culture propagation, and this may in turn be related to observed differences in tropism among clinical isolates and laboratory strains (9, 106). Interestingly, CMV infection of microvascular EC promotes monocyte activation, migration, and infection, which may be a potential mechanism of viral dissemination into the brain (29).
In contrast to astrocytes, primary differentiated human neurons are refractory to CMV replication. Highly purified primary neuronal cultures (>90% neurons) contain a small percentage of dividing astrocytes that support viral replication, but viral gene products cannot be detected in neurons (157). The block in viral replication is effected at the level of the major IE promoter (MIEP), not during viral entry (51). The human CMV MIEP, one of the first viral transcriptional regulatory elements activated in a susceptible cell, has numerous transcription modulator elements that may be regulated by the state of membrane polarization or cell differentiation (51, 207, 281). The inhibition of MIEP-mediated transcription in resting neurons is effectively reversed by membrane depolarization. The induction of MIEP activity by potassium-mediated depolarization is dependent on activating the cyclic AMP response element binding protein (CREB) binding elements (281). This observation may have relevance for the pathogenesis of CMV-associated labyrinthitis, since the endolympathic compartment of the cochlea is a high-potassium, low-sodium environment, whereas the perilymphatic compartment consists of a low-potassium, high-sodium milieu (280). Furthermore, a recent study demonstrated that the MIEP block in neurons can be synergistically reversed by activating the cyclic AMP signaling pathway and inhibiting histone deacetylase-mediated viral gene silencing (130, 172). Similar experiments with undifferentiated human oligodendrogliaoma cells, representative of immature oligodendrocytes, demonstrate that oligodendrocytes, like neurons, may not be fully permissive for CMV infection. However, CMV IE, US11, and gB gene expression is induced in human oligodendrogliaoma cells upon differentiation with phorbol myristate acetate, without production of viral progeny (253). Taking these findings together, it appears that the state of cell differentiation as well as functional status may modulate permissiveness to CMV brain infection in utero.

Microglia, the end-differentiated resident brain macrophages, also do not support productive CMV infection (157). CMV DNA has been demonstrated in infected microglial cells in the absence of detectable viral IE proteins (212, 213). Although controversial, it is believed that brain microglia may be replenished from bone marrow-derived precursors that migrate into the brain (reviewed in reference 223). It has been shown in many studies that myeloid precursor cells may be a site for CMV latency and a vehicle of viral dissemination in the host (105, 122, 136). Although myeloid precursors and monocytes are not productively infected by CMV (135, 145), they support productive CMV infection at certain stages of differentiation (247). In addition, EC-adapted viral strains have been shown to infect both macrophages and dendritic cells (93, 244). It is not known if brain macrophages are a potential source of viral infection during fetal development, but the proximity of vascular macrophages to CMV-susceptible cells in the CNS could play a major role in viral dissemination into the brain.

**PATHOGENESIS**

**Developmental Biology Paradigm: Is CMV a Teratogen?**

Although it is often stated that CMV is a teratogen for the developing fetus, there is in fact little evidence to support a direct teratogenic role in developing fetal tissue. However, several studies suggest that CMV infection may lead to birth defects, either by direct chromosomal injury or by modulation of developmental gene expression. In a study using human fibroblasts, infection with CMV during the S phase of the cell cycle resulted in two specific chromosome 1 breaks at positions 1q42 and 1q21. Purified virions, and not infected cell supernatants alone, were responsible for the effect, which could be blocked by coinoculation of virus with neutralizing antibody. UV-inactivated virus was as efficient as untreated virus in inducing specific damage to chromosome 1, suggesting a requirement for viral adsorption/penetration but not de novo viral gene expression (80). Two loci present near this breakpoint may be of particular interest: DFNA7 and USH2A. The DFNA7 gene has been linked to the inheritance of an autosomal dominant, nonsyndromic, progressive form of hearing loss (74). Perturbation of the DFNA7 gene caused by CMV-induced breakage could conceivably be linked to the development of the progressive SNHL. The USH2A gene, which is physically closest to the most prevalent CMV-induced break described by Fortunato et al. (80), encodes a protein important in the pathogenesis of Usher’s syndrome type II, an autosomal recessive disorder responsible for both SNHL and blindness (73, 263). The possible relationship between these chromosomal breaks and the CMV-induced sequelae of SNHL, as well as a possible link to the visual impairment caused by CMV, requires further experimental evaluation.

**Apoptosis and Cell Cycle Changes**

Programmed cell death, or apoptosis, is a mechanism whereby damaged or infected cells are eliminated from the tissue by an “autodestructive pathway” so as to maintain homeostasis. The apoptotic process is essential for the elimination of damaged or poorly developing cells during organogenesis and is also considered a critical defense mechanism to purge virus-infected cells from the host. To sustain a relatively slow replication cycle and the propensity to establish a lifelong infection in the host, the CMV genome has retained gene products that serve as countermeasures against cellular antiviral processes, including apoptosis. Two distinct pathways mediate apoptosis in the mammalian cell. One, the intrinsic pathway, triggers cellular sensor proteins such as p53 and initiates a cascade of biochemical signals leading to the mitochondrial release of cytochrome c. The other is an extrinsic pathway activated by external signals, primarily involving the immune system, and consequent phosphorylation of receptor death domains, such as those in the tumor necrosis factor (TNF) receptor family and FAS, by their respective ligands. Apoptotic signals, both intrinsic and extrinsic, converge to induce the activation of the caspase family of proteases. These eventually lead to proteolysis of the cell architecture, metabolic derangement, genomic fragmentation, and cell death. Viral replication and biosynthesis constitute a cell stressor that results in the inevitable outcome, cell death (reviewed in references 27 and 28).

CMVs have evolved mechanisms to delay the intrinsic apoptotic signaling pathway, presumably to allow time for completion of their relatively slow replication cycles. The viral IE proteins, IE1 and IE2, which are the major transcriptional
regulators of viral replication, are known for their ability to inhibit apoptosis (290). When infected with CMV, human astrocytes turn over phosphatidylserine molecules to the extracellular surface, an early cellular alteration that marks apoptotic cells for destruction by macrophages. However, the subsequent nuclear changes in the apoptotic cycle are delayed (i.e., DNA degradation) until later in the viral replication cycle (157). Viral replication in astrocytes and other cells is known to induce the proapoptotic cell sensor p53 (157, 178, 252). Inhibition or delay of late apoptotic events in CMV-infected cells is associated with sequestering of cytoplasmic p53 by viral IE2 (157, 268). However, CMV IE genes by themselves are not sufficient to prevent cell death. Human CMV carries two anti-apoptotic genes that suppress virus-induced apoptosis in the late replication phase. The CMV UL36 gene encodes the viral inhibitor of caspase 8 activation (vICA), and UL37 (exon 1) encodes viral mitochondrion-localized inhibitor of apoptosis (vMIA) (97, 219, 246). vICA inhibits apoptosis by binding to procaspase 8 and prevents its activation to an active form (246). Rodent and macaque CMVs also carry a UL36 homolog, but M36 (the murine CMV [MCMV] homolog) appears to be essential for viral replication in vivo (96, 170). On the other hand, vMIA inhibits apoptosis by interacting with Bax (a proapoptotic molecule) and sequestering it within the mitochondrial membrane as an inactive form (97). vMIA physically interacts with cytosolic Bax to form high-molecular-weight oligomers and subsequently prevents the formation of the mitochondrial permeabilization core complex and release of cytochrome c (14, 209). Viral replication requires expression of vMIA, and deletion of the gene can be counteracted by inhibiting cellular apoptotic responses using caspase inhibitors or the adenoviral E1B 19-kDa antiapoptotic protein (219). In addition, vMIA disrupts the mitochondrial reticular network formation (171) and is responsible for the cell architectural changes during infection (210). Additional viral genes, whose mechanisms of action have yet to be elucidated, are known to inhibit apoptosis in infected cells, such as UL38 of CMV, which blocks caspase-dependent apoptosis (267), and the MCMV gene M41, identified as a Golgi apparatus-resident apoptosis inhibitor (43). Given that homologs of some antiapoptotic viral genes have been identified in both rodent and macaque CMVs (170), it has now become possible to experimentally investigate the in vivo relevance of viral functions that subvert cell death processes during congenital CMV brain infection.

While inhibition of cell death may be essential for virus survival in the susceptible host, apoptotic neuronal damage is observed in brains of patients with congenital CMV infection, particularly around the periventricular zone. However, post-mortem examination of brain tissue from patients who developed neurological sequelae due to a symptomatic congenital CMV infection indicates that neuronal and glial apoptoses are absent or rare, with spatial and temporal distance from the initial acute viral infection (64). Viral gene products are absent in areas associated with neuronal apoptosis. Similarly, in the mouse model of CMV brain infection, neuronal apoptosis in MCMV-infected brains is seen in areas both close and distal to the infection site, but the dying cells rarely demonstrate the presence of viral antigen (241). This phenomenon, indicative of bystander apoptosis in uninfected cells, has also been observed in CMV infection of the retina (32). The lack of association between viral products of infection and apoptosis in vivo is further substantiated by the resistance of infected neurons to glutamate-induced apoptosis in vitro (141). This suggests an indirect role for virus-induced neuronal loss by apoptosis. One of the mechanisms of indirect neuronal loss can be explained by virus-induced neuroinflammatory responses, involving cytokines, chemokines, and metabolic intermediates that result in neurotoxicity around and distal to the infection site.

The TNF family of ligands, which includes FasL/Apo1L/CD95L and Apo2L/TRAIL (TNF-related apoptosis-inducing ligand), are extrinsic apoptosis signals expressed in response to tissue injury or inflammation. The ligation of death receptors by FasL and TRAIL induces the direct activation of upstream caspases in the apoptosis signaling cascade (15). FasL, but not TRAIL, is expressed in the CNS along with all of its cognate receptors. The expression of FasL is upregulated during inflammation, presumably to “kill” infiltrating activated T cells and prevent irreparable damage to the CNS. Very little is known about the extrinsic apoptotic pathway in the brain, but there is increasing evidence of its role in regulating normal brain development and its compromised state in neurological disorders (reviewed in references 57 and 183). The human eye is yet another immune-privileged site, like the brain, where retinal cells express FasL and TRAIL. CMV infection of retinal pigment epithelial (RPE) cells upregulates FasL expression, via transactivation by the viral IE2 gene product, which in turn induces apoptosis of T lymphocytes (55, 59). Interestingly, cells that are IE2 positive, but not the IE-negative bystander RPE cells, are resistant to FasL-induced apoptosis. The IE2-mediated block in apoptosis in RPE cells is associated with the induction of expression of cellular cFLIP (Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein), an antiapoptotic molecule that inhibits the activation of caspase 8 by FADD (Fas-associated protein with death domain). CMV IE2 expression also inhibits TRAIL-induced apoptosis in retinal cells, indicating that the block is indeed mediated at the level of a common signaling molecule (FADD) in the apoptosis pathway (56). Similar upregulation of FasL and TRAIL is seen with CMV infection of dendritic cells, indicating that the virus may have evolved a multilayered immune evasion strategy, which in turn may result in the apoptotic damage of bystander cells (56, 216).

In addition to inhibiting apoptosis, CMV IE and early gene products IE 72, IE86, pp71, and pUL69 alter cell cycle progression in human fibroblasts by interacting with cell cycle regulatory proteins. In quiescent fibroblasts, CMV infection quickly (in 6 to 12 h) activates cell cycle regulatory proteins and accelerates cell cycle progression from G0/G1 to early S phase. At later stages of infection, when viral DNA replication is initiated, progression of cellular DNA synthesis is inhibited, and the cell cycle is arrested at a pseudomitotic (G2/M) stage, where chromosome segregation and cytokinesis are blocked (41, 114, 123, 159, 249). Inhibition of cellular DNA synthesis is essential for viral replication (202). Modulation of cell cycle progression in infected cells enables the virus to maximize the availability of cellular DNA replication machinery without competition from the cellular genome for the same resources (for a review, see reference (46). In the developing brain, CMV productively infects astrocytes and neural precursor cells, cell
types known for their ability to undergo cell division in vivo. However, as noted, neurons, a terminally differentiated cell type, are not permissive to productive viral infection (51, 157, 167). It is likely that cell cycle alterations in the neural stem/precursor cell populations residing in the ventricular regions of the brain are critically important in the neuropathogenesis of congenital CMV infection. However, very little is known about the effects that viral infection has on neural stem cells (see below), except that infection inhibits cell proliferation and alters differentiation profiles (51, 190, 191).

**Neural Stem Cells in CMV Infection**

Neural stem/precursor cells, located predominantly in the subventricular zone and subgranular zone of the hippocampus in the adult mammalian brain, have taken center stage in medical research because of their ability to migrate, proliferate, and differentiate into neurons, astrocytes, and oligodendrocytes. These cells potentially can repopulate damaged brain cells and aid in the establishment of new neuronal circuits during memory formation (89, 182, 266). In brain infections of both congenitally infected children and adults, CMV preferentially infects cells in the ventricular or subventricular regions (100, 201, 236), indicating the possibility of CMV replication in the neural stem/precursor cells residing in the region. With currently available protocols it is now possible to maintain human neural precursor cells in culture and differentiate them into neurons, astrocytes, and oligodendrocytes (182). At least a few studies have demonstrated that human CMV replicates efficiently in undifferentiated human neural precursor cells in vitro (51, 167, 190). The extent to which these versatile cells are infected in utero may determine the outcome of CNS sequela associated with congenital CMV infection. During differentiation, susceptibility to CMV infection could then be retained in glial cells but not in differentiated neurons. The apparent refractivity of differentiated neurons to CMV infection may, at least in part, be explained by expression of the transcription factor C/EBP β, including a dominant negative isoform that retains its DNA binding domain but has lost the transcriptional activation domain (194). The CMV MIEP has C/EBP binding sites immediately downstream from its proximal NF-κB binding sequence. The dominant negative isoform of C/EBP binds to these enhancer regions and inhibits transcription from the CMV MIEP (51, 211). This is yet another possible mechanism for repression of viral gene expression in neurons. CMV infection of human neural precursor cells inhibits their differentiation into both neurons and astrocytes, perhaps due to virus-induced apoptosis in cells undergoing differentiation (190, 191). CMV replication also inhibits neural precursor cell proliferation, possibly by altering cell cycle mechanisms (51, 191).

It is possible that disruption of cellular processes in neural precursor cells may indeed account for a large portion of the structural and migratory abnormalities seen during congenital human CMV infection. The neural stem cell niche in the mouse has been well defined and extensively studied. The subependymal area around the ventricles in murine models of CMV brain infection is selectively predisposed to CMV infection. Ex vivo cultures of thin brain slices, also called organotypic brain cultures, are useful models to determine cell susceptibility to CMV infection while keeping the three-dimensional architecture of the organ intact. MCMV infection of neural stem cells inhibits their growth and decreases their ability to differentiate into neuronal phenotypes. However, like their human counterpart, stem cells differentiated into glia retain their susceptibility to CMV infection in the mouse (139). Virus-infected cells in organotypic brain cultures immunostain for GFAP (an astrocyte marker) and for nestin and Mushashi (stem cell markers). The susceptibility of brain cells to CMV infection in an organ culture system does not differentiate between C57BL/6 (a relatively resistant strain) and BALB/c (a susceptible strain) mouse brains (128), indicating that strain-dependent differences in resistance to CMV infection are not mediated by an altered susceptibility of the brain cells themselves. There is, however, a lack of infection in mature neurons in the murine model.

It is not clear if MCMV IE2 expression in neurons, which is sustained in cortical neurons up to 2 weeks postinfection (120). The susceptibility of brain cells to CMV infection in an organ culture system does not differentiate between C57BL/6 (a relatively resistant strain) and BALB/c (a susceptible strain) mouse brains (128), indicating that strain-dependent differences in resistance to CMV infection are not mediated by an altered susceptibility of the brain cells themselves. There is, however, a lack of infection in mature neurons in the murine model. Although neural stem cells are present in relatively small numbers in the adult mouse brain compared to the fetus or neonate, they are also susceptible to CMV infection (Fig. 2). Interestingly, the primordial embryonic stem (ES) cells are refractory to MCMV infection, which is similar to the case for neurons (the prototypic end-differentiated cell). As the ES cells differentiate toward a glial phenotype, they become susceptible to CMV infection (166), indicating that the state of cellular differentiation may play an important role in determining susceptibility to CMV infection, most likely determined by the cellular transcriptional factor milieu.

Infection of neural stem cells may affect not only prenatal development but also postnatal neuronal development. In mouse studies, fetal brain infection at embryonic day 14.5 (E14.5) to E15.5 shows a dramatic decrease in the numbers of developing neurons (determined by bromodeoxyuridine pulsing) migrating to distal cerebral cortical layers II and III, by half at postnatal day 7. The deeper layers of the cortex (III and IV) were inundated with both infected and immature neuronal cells, indicative of impeded migration of developing neurons to the distal cortical layers (241). CMV infection from the ventricular region is presumed to be carried into the cortical structures by migration of developing neurons. Similar delayed migration of infected neurons is also seen in the cerebellar cortices of CMV-infected neonatal mice. Although postnatal development of the cerebellum is only delayed and not arrested, the delay in development is associated with decreased proliferation and differentiation of granular neuron precursors, potentially mediated by the loss of response to neurotrophins in infected precursors and the induction of inflammatory responses in mononuclear cells (137).

It is interesting to note that infected neural cells retain their ability to migrate, albeit aberrantly (137, 241). CMV-infected migrating neurons express only 1E antigens, but glial cells, particularly those seen around the ventricles, express both the IE and late viral proteins (242). The 1E viral proteins, IE2 (M128) and IE3 (M122), are expressed in the immature neuronal cells lining the ventricular zone, which decreases as the infection progresses. Additionally, CMV IE expression diverges with differentiation of immature cells in the neonate; IE3 is expressed predominantly in glial cells and IE2 in neurons. Expression of IE2 is concentrated in the cortex and is sustained in cortical neurons up to 2 weeks postinfection (120). It is not clear if MCMV IE2 expression in neurons, which is
generally considered to be nonessential for viral replication (163), will alter neuronal physiology.

**Developmental Susceptibility to CMV Infection**

Neurological symptoms due to CMV infection are relatively unique to congenital infection. In the CMV-infected adult, neurological complications are rare, except in cases of severe immunodeficiency (such as in advanced AIDS and organ transplant patients). The mechanisms that relate to differences in the manifestations and frequency of CMV-induced brain disorders are poorly understood. One explanation for varying disease manifestations may be directly related to the presence of a higher proportion of actively dividing immature neural stem cells in the fetal brain at different fetal ages. The human brain begins development as a thin sheet of neuroepithelial cells that proliferate rapidly to form the neural tube, as early as 4 weeks of gestation. The center of the neural tube ultimately forms the ventricular system, while the neuroepithelial cell divides asymmetrically, along the longitudinal and horizontal axis and in thickness, to form the different brain regions, while sustaining the astrocyte-like neural stem or progenitor cells in the subventricular zone (reviewed in reference 174). The active proliferation of neuroblasts occurs between 5 and 25 weeks of gestation, and the bulk of glial cell development takes place between 20 and 40 weeks. Development of the cortical layer, however, begins as early as 7 weeks, and immature neurons migrate to new regions along a radial axis and form neural networks (reviewed in reference 65).

Neuroepithelial cells (167) and neural progenitor cells (51) isolated from developing human brain tissue are susceptible to CMV infection. In contrast, undifferentiated ES cells do not sustain viral replication (98, 143). The block in viral replication appears to be at the MIEP, with expression being significantly suppressed in human ES cells (143, 286). Given these data, it can be assumed that while the early embryo is not susceptible to CMV infection, the fetus may be infected at as early as 4 weeks of gestation. CMV infections at different gestational ages may have distinct effects on the cellular and developmental patterning of the brain that may ultimately determine neurological outcomes.

While the neuropathogenesis of human CMV infection is not clearly understood, mouse models of congenital CMV infection demonstrate that susceptibility to CMV and outcomes of brain abnormalities are directly related to the gestational age at infection (270). Similar to the case for human ES cells, mouse ES cells do not support productive CMV replication but become susceptible upon differentiation to a glial phenotype (166). In concordance, early blastocysts and postimplantation mouse embryos are not prone to CMV infection, presumably due to a lack of susceptible cells. The mouse embryo acquires permissiveness at E7.5 (125). Infection at the midgastrulation stage (E8.5) results in the development of microphthalmia and cerebral hypoplasia due to infection in the mesodermal tissue (269). Infection of the placenta, at E12.5, results in CMV brain infection, and 25% of the mice showed evidence of microcephaly and growth retardation associated with viral infection in the brain (271). The virus, in animals with brain infection...
(27%), was located predominantly in the subventricular zone, a region where the neural stem cells also reside (271). Adult mouse brains infused with epidermal growth factor to stimulate neural stem cell proliferation showed higher levels of infected cells and viral titers in the brain (108), suggesting that the susceptibility of adult brains depends on the quantity of neural stem cells present. The numbers of susceptible cells, including neural stem cells and immature glial/neuronal cells, decrease as the brain develops into adulthood and the spatial distribution of susceptible cells becomes more localized to the ventricular and cortical marginal areas (128). It is unclear how the infection of these neural stem cells may affect the neurological outcomes of CMV brain infection.

Second, it is unwise to overlook the possibility that altered fetal immune responses to CMV may explain the increased susceptibility to neuronal abnormalities due to congenital infection. Initial immune responses to viral brain infection are mediated through the nonspecific cellular responses of macrophages, microglia, and NK cells, as well as through the production of cytokines and other soluble mediators by the resident glial cells (astrocytes and microglia). After this initial innate response, adaptive immunity develops and mediates antigen-specific defenses. Both innate and adaptive responses are critical components for defense against viral brain infection (49). In the mouse model, CMV infection in the neonate generates an attenuated interferon (IFN) response compared to a similar infection in the adult (273). Whether the attenuated response is due to a poor glial cell response or proportionally lower numbers of glial cells in the neonate needs to be defined. Neonatal mice infected with CMV in the CNS show evidence of activation of NK cells and macrophages (139). While these local tissue responses are induced by CMV, their involvement in the clearance of viral infection is currently speculative. In addition to the innate responses by resident glial cells, adaptive responses in the fetus may be altered and thus may predispose to CMV infection (see below).

Neuroinflammatory Processes

The traditional view that the brain is immune privileged due to its immunological inert nature and physical separation from the somatic immune system has been dramatically changed by a number of studies in the last decade (90). It is now clear that local CNS cellular responses, mediated largely by astrocytes and microglia, and the somatic immune system interact actively during brain infections. Neuroinflammation has both protective and neurotoxic effects that mediate the outcome of an insult. It is now known that a myriad of CNS-specific responses modulate effector functions of both resident glial cells and infiltrating somatic immune cells, resulting in a specialized response that mediates immune privilege (45).

Ontogeny of the immune response. The increased susceptibility of the fetus and neonate to many viral infections, including human immunodeficiency virus (HIV), CMV, and herpes simplex virus, is not due to a lack of immune effectors but is associated with their decreased reactivity to antigen compared to adult immunocytes (reviewed in reference 10). Immune cells develop as early as 3 to 4 weeks of gestation, at which time the human embryonic yolk sacs show evidence of granulocyte, macrophage, and erythroid precursors. These primitive immune cells migrate from the yolk sac to the liver by 6 weeks to form the first fetal hematopoietic organ. The liver provides the niche for further differentiation of primitive precursor cells to macrophages, pro-T and pro-B lymphocytes, and granulocytes. The spleen is fully developed and functional by 18 weeks of gestation, with adequate numbers of functional accessory cells available for antigen presentation. Mature fetal T and B cells are first seen in the fetal circulation as early as 16 weeks of gestation (the development of the immune system in mouse and humans has been extensively reviewed [24, 118, 177]).

Altered immune responses of the fetus may increase susceptibility. Both clinical and experimental evidence demonstrates that the immune system during pregnancy is skewed to elicit predominantly Th2 responses, thus altering host susceptibility to various pathogens (121). Cytokines, such as interleukin-10 (IL-10), IL-5, and IL-4, predominate at the materno-fetal interface of the placenta, which is essential for maintenance of pregnancy (38, 47). It has been postulated that the microenvironment at the materno-fetal interface selectively downregulates Th1 responses in the fetus, resulting in decreased IFN-γ production, while B cells continue to respond to antigen stimulation to produce IgG and IgM antibodies (118).

Congenitally infected human fetuses can elicit a robust cell-mediated immune response composed predominantly of CD8 lymphocyte effectors, with lower numbers of activated CD4 T cells. Immunophenotypic analysis of the lymphocyte response indicates a switch in circulating T cells toward higher proportions of CMV-specific activated and terminally differentiated effector phenotype (HLA-DR+, CD95+, and CD45RA− CD28−) as early as 22 to 29 weeks of gestation (72, 164). However these effector CD8+ cells were poor IFN-γ producers in response to CMV antigens (72, 112) and had lower levels of perforin-positive activated cells, although they produced granzyme A (164). The CD8 T-cell response is directed predominantly to two viral proteins, IE1 and pp65. The IE1-specific T cells are detectable for up to 1 year after birth and form the bulk of the T-cell response to CMV later in life (95). The early responses to pp65 and IE1 are elicited by peptides derived from multiple regions of the viral proteins, and the peptide recognition repertoire broadens with age (94). While it is suggested that the CD8 T-cell responses are protective against CMV, it is not clear if decreased cytokine responses or differences in peptide recognition patterns in the fetal response determine the neurological outcome of congenital CMV. Gaining insights into the role of T-cell responses in fetal infection will help in the design of better vaccines for CMV infection. CD8 T cells are critical in protection against MCMV brain infection (21, 49). Interestingly, the lymphocyte response to neonatal brain infection shows a preponderance of CD8+ T cells and is focused against a single immunodominant IE1 epitope (IE1 exon 4168–176) during the acute phase (21). The relevance of immune responses to specific epitopes and their role in protecting against CMV brain infection is still unclear. Nevertheless, investigations such as this in animal models of congenital infection need to devote increased emphasis to the study of the fetal cellular response to CMV infection in utero.

Cytokine-mediated damage. It is well documented that immune responses in the CNS are mediated by both resident brain cells and immune effectors that infiltrate brain tissue in response to infection or injury. Resident glial cells are the
intrinsic sensors in the brain and respond quickly and effectively to neurological insults through the production of soluble mediators, i.e., cytokines and chemokines (reviewed in references 158 and 243). While some of these cytokines have neuroprotective function, overexpression of cytokines may result in neurodegeneration and damage within the CNS (181). Therefore, effective regulation of the innate and adaptive immune responses in the CNS may play a critical role in maintaining the delicate balance between the control of viral infection and immunopathology.

Cultured human glial cells, derived from 16- to 20-week-old fetal brain tissue, respond to CMV infection by expressing a number of immune mediators, including chemokines and cytokines (223). Astroglial cells, which constitute 70% of brain cells, produce chemokines in response to CMV infection. The chemokine response by astrocytes is predominated by the production of CCL2 and less so by the production of CXCL8, CCL3, and CCL5 (53, 54). Interestingly, the cytokine response to CMV infection in astrocytes is restricted to transforming growth factor β, an anti-inflammatory cytokine, which may have an effect on viral replication (138), but none of the proinflammatory cytokines tested (TNF-α, IL-1β, IL-6, IFN-α, IFN-β, and IFN-γ) were found to be induced. On the other hand, microglial cells (resident brain macrophages) respond to CMV infection by producing TNF-α and IL-6 as well as CXCL10, CCL2, CCL3, and CCL5 (53, 54). The proinflammatory cytokines TNF-α and IFN-γ inhibit viral replication in astrocytes by suppressing the CMV MIEP (50). TNF-α-induced transcriptional inhibition of the MIEP was mediated at a specific region of the enhancer situated between bp –583 and –242 (Fig. 3). This distal enhancer region is essential for viral replication, but the requirement can be overcome by using a higher multiplicity of infection (173). These findings suggest that proinflammatory cytokine production in the brain may have a protective role in controlling viral spread.

Chemokines are responsible for recruiting peripheral im-
mune cells into the CNS during infection (119). In a mouse model of CMV brain infection, we have demonstrated that active recruitment of T cells into the CNS is essential for protection. While the initial infection established during the first 3 days is controlled in the absence of peripheral lymphocytes, sustained protection and control of viral spread within the CNS are mediated by a perforin-dependent cytotoxic (CD8\(^{+}\)) T-cell response. Viral infection also induces CXCL9 and CXCL10, which are known T-cell chemoattractants that precede lymphocyte infiltration. In addition, the infiltrating lymphocytes, which are a source for IFN-\(\gamma\) in the brain, transiently amplify the virus-initiated CXCL10 response (48, 49). This acute cytokine response, although not critical for protection against CMV brain infection in this model, is regulated by the anti-inflammatory cytokine IL-10. Interestingly, lack of IL-10 expression leads to a severely dysregulated IFN-\(\gamma\) response and renders a benign CMV brain infection lethal. Although lack of IL-10 has little effect on viral clearance, the levels of IL-6, IFN-\(\gamma\), CXCL10, and CCL2 are dramatically increased. However, not all the cytokines are dysregulated in the absence of IL-10; TNF-\(\alpha\), IL-1\(\beta\), and CCL5 levels are relatively unaffected (52). Interestingly, human CMV carries its own IL-10 homolog that inhibits CXCL10 production in human microglial cells, which consequently inhibits lymphocyte migration (53). An analogous IL-10 homolog has not been identified in MCMV. The IL-10-mediated control of IFN-\(\gamma\) responses in the infected mouse brain is mediated predominantly by CD45\(^{hi}\) CD11b\(^{+}\) cells, a phenotype that characterizes infiltrating lymphocytes (52). The brain-infiltrating leukocyte profile in the absence of IL-10 and the mechanisms that regulate cytokine induction in brain cells are currently under investigation. It appears that protection against CMV infection and the regulation of cytokine responses are mediated by distinctly separate mechanisms, both of which are essential for protecting the brain from deleterious consequences of viral infection.

It is known that infiltration of peripheral cells into the brain and the resultant production of the proinflammatory cytokine milieu are the first steps leading to many neurological disorders (195). However, the mechanisms that cause neurotoxicity during CMV brain infection are not fully understood. There is evidence for two possible paradigms for cytokine-induced brain damage: (i) cytokines and their inducible cellular byproducts are neurotoxic, or (ii) cytokines produced in response to viral infection alter neural stem cell migration and differentiation. Recent studies of neonatal CMV infection in mice have suggested that the delay in cerebellar development due to infection is associated with the inflammatory response which transiently perturbs the developmental program (137). More studies are needed to determine the contributions of these mechanisms to CMV neuropathogenesis.

**Placental Insufficiency: Vascular Damage, Hypoxia, and Altered Permeability**

The efficiency of viral transmission at the different stages of placental development may influence fetal infection. The placenta, a six-layer barrier that separates the maternal and fetal circulations, is progressively eroded by the invasion of trophoblasts into the maternal decidua, ultimately fusing together to form syncytiotrophoblasts (107). It is not until the second trimester that the invasion of trophoblasts effectively fenestrates the maternal bloodstream enough to allow exchange of oxygen and nutrients between the maternal and fetal blood to occur. Although there is evidence that CMV-related pathology is mediated by direct infection of the fetus, recent studies have shown that while the placenta serves as an amplifying reservoir and effective conduit for viral transmission, CMV infection of placental cells may also contribute to the pathogenesis of congenital CMV infection by altering placental formation, ultimately resulting in placental insufficiency (6, 200).

CMV infection of placental cytotrophoblasts perturbs their cellular gene expression profile. Of note is the robust repression of genes associated with trophoblast differentiation and invasion and with formation/stabilization of the extracellular matrix (230). CMV infection markedly decreases the expression of \(\alpha\)1\(\beta\)1 integrin (laminin/collagen receptor) and other integrin molecules (\(\epsilon\)9 and \(\beta\)6) on cytotrophoblasts. Consequently, CMV-infected trophoblasts demonstrate impaired cell adhesion and invasion properties (78, 161). In addition, viral infection activates the expression of matrix metalloproteinases (MMP), in particular MMP9, in the placenta and inhibits expression of HLA-G molecules on cytotrophoblasts (78, 287). Upregulation of MMP9, together with the expression of integrin molecules and tissue inhibitor of metalloproteinases, is essential for coordinating placental remodeling and modulating the depth of trophoblast invasion during normal development (25). Human CMV infection of trophoblasts results in the expression of the viral IL-10 homolog and also induces cellular IL-10, both of which inhibit MMP9 expression in placental cells (287). It is interesting to note that cellular proteins dysregulated during CMV infection of placental trophoblasts are similar to those altered in preeclampsia, a condition characterized by poor placentaion and intrauterine growth reduction (6, 152).

The timing of trophoblast infection during gestation would determine pregnancy outcomes associated with placental insufficiency. Trophoblast infection seen during the first trimester in chorionic villi (199) could adversely affect placental development. Infection of the trophoblast early in gestation can impair proper implantation and hence contribute to pregnancy loss. In the later stages of pregnancy, improper development of the placenta may result in intrauterine growth reduction and other fetal outcomes resulting from placental pathology. Ultrasound examination of the placenta at between 16 and 36 weeks of gestation showed a significant thickening in pregnant women with primary CMV infection. Placental pathology is strongly associated with fetal and neonatal disease (147). In addition, it is possible that CMV-mediated inhibition of the immunoregulatory major histocompatibility complex molecule HLA-G increases the susceptibility of invading trophoblasts to elimination by the maternal immune response, further endangering placental formation. Hence, it is plausible that some of the clinical features of cytomegalic inclusion disease could be explained by fetal hypoxia resulting from placental insufficiency and hypoperfusion, which could in turn contribute to the pathogenesis of brain abnormalities such as polymicrogyria. Many of these symptoms are resolved after birth, presumably with proper nutrition and adequate oxygenation. Furthermore, postnatal CMV infections are not associated with
the symptoms described for placental insufficiency, suggesting that placental insufficiency may play a critical role in the pathogenesis of congenital CMV (6).

**ANIMAL MODELS**

Although many elegant experiments investigating the pathogenic mechanisms of CMV brain infection have been performed in animal models, an obvious caveat with these animal systems is the strict host specificity of CMVs, requiring the use of viruses that may have a different biology than their human counterparts. However, these systems have been used to model many aspects of congenital infection, including neuropathogenesis and responses to vaccines which could not otherwise be tested for efficacy. The development of CMV cross-species chimeras has also helped bridge some genetic differences among this group of viruses.

Given this caveat, CMVs have comparable genetic makeups, with many genes that have both sequence and functional homologs. They generally have similar pathogenic mechanisms in their host species, which can be used to model human CMV infections. Among the animal models for CMVs (summarized in Table 1), only guinea pig CMV (GPCMV), porcine CMV (PCMV), and rhesus macaque CMV (RhCMV) are known for their ability to cross the placental barrier during a natural infection, resulting in fetal infection (reviewed in reference 228). Anatomically, the guinea pig and the rhesus macaque placentations are classified as hemomonochorial, similar to the case for the human placenta, and are characterized by distinct villous projections, cytotrophoblast invasion, and fenestration of maternal blood vessels that extend into the maternal myometrium. However, anatomical differences in the placental structure, fetal fenestrations into the maternal blood vessels, and extent of fetal-maternal interaction alone do not contribute to in utero transmission. Structurally, the pig placenta forms a more robust placental barrier with a relatively unique epitheliochorial anatomy. During natural infection, PCMV can be transmitted to the fetus, producing disease in multiple fetal organs systems (70). Interestingly, a recently isolated strain of rat CMV (RCMV) strain, ALL-03, has been shown to cause congenital infection in the pregnant rat (156). In addition, the mouse placenta can also be infected with CMV in severely immunodeficient mice, demonstrating pathological outcomes.
similar to those of human congenital CMV infection (285). Regardless of the mechanisms of transmission into the fetus, the ability of the virus to infect the brain is the single most important contribution to prognosis of CMV infection in the neonate (48, 221, 269) and hence is a critically important experimental end point to keep in perspective in the study of animal models of CMV-associated diseases.

Murine Model

MCMV models have provided tremendous insights into CMV neuropathogenesis and the role of immune responses in controlling infection (48, 221, 271). The advantages of using the murine model are as follows: (i) the fact that the characteristics of CMV infection in the mouse are comparable to those of human CMV infection, in that CMV infection in the immunodeficient host and the fetus renders pathology and symptoms similar to those seen during human infection; (ii) the similarity of the MCMV genome to the human CMV genome at the genetic and nucleotide composition levels, making it a useful model to assess the role of viral genes in disease pathogenesis (218); and (iii) a well-characterized immune system, a relative small animal size, short gestational periods, and the availability of a large number of reagents, including transgenic and knockout animals. In mice, since they are altricial mammals, many developmental processes continue to occur during the postnatal period, enabling the use of neonates to investigate effects of infection on brain development.

With rare exceptions (285), the placental barrier is presumed to be refractory to CMV transmission in the mouse, most likely due to effectiveness of the three-cell-thick trophoblast layer that separates the maternal and fetal circulations. When this placental barrier is circumvented, by direct infection of either the placenta or embryo, the fetal brain becomes susceptible to CMV infection (151, 269). Susceptibility of the brain increases with the age of the fetus. The earliest infection of the embryo can be demonstrated after E7.5, whereas early blastocyst and ES cells are refractory to MCMV infection (125, 166). MCMV-infected blastocysts implanted into mice show neither signs of abnormal implantation nor developmental abnormalities. The embryos tested at E11 are not positive for viral antigens (270). Virus-positive cells are seen predominantly in the ventricular zone and subventricular zone and occasionally in the pyramidal layer of the hippocampus and some cortical regions when infection is at later stages of gestation (151). Embryos that survive late gestational infection often show signs of growth retardation and microencephaly. During the course of maturation from neonate to adult, the susceptibility of brain to CMV infection decreases. It is postulated that this decrease in susceptibility may be due to an age-dependent decrease in the number of susceptible cells in the developing brain (128) or to an age-dependent increase in the ability of the immune response, both innate and adaptive, to protect against infection (139).

The physiological effects of CMV infection on neurons have not been well studied. It is possible that the brain may serve as a site for viral latency, based on the long-lasting expression of MCMV IE genes in the cortices of in utero-infected mice, presumably as a result of maturation of infected neural stem cells into neurons (120). MCMV-infected neurons display altered electrophysiological responses as early as 24 h postinfection (273). The resting potential of infected neurons becomes significantly depolarized (i.e., becomes more positive) and hence attenuates amplitude, duration, and frequency of evoked action potentials. In addition, stepwise enhancement of voltage-evoked electrophysiological responses is significantly attenuated in MCMV-infected neurons (273). The N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor subtype seen on both neurons and glial cells, plays a central role in higher brain functions, such as memory and learning, by mediating an influx of Ca\(^{2+}\) ions (276). CMV infection of neonatal brain markedly decreases expression of NMDA receptor subunit 1 in the CA1 neurons of the hippocampus. This decrease in NMDA receptor subunit 1 attenuates neuronal responses to glutamate, in that glutamate-induced excitotoxicity is dampened in infected neurons (140). Whether electrophysiological changes in the infected neuron result from a decrease in ion channels or disruption of other intracellular processes is as yet unknown. Furthermore, the implication of these findings for the pathophysiological outcome of congenital CMV infection needs further investigation.

Guinea Pig Model

Among the small animal models of congenital CMV infection, GPCMV offers some unique advantages compared to rodent models. Chief among these advantages is the fact that GPCMV crosses the guinea pig placenta, causing infection in utero. Thus, the guinea pig model is particularly well suited to the study of vaccines designed to interrupt transplacental transmission of infection. The unique biology of the guinea pig and the use of this model to study congenital CMV infection are briefly summarized below.

The biology of the guinea pig has been the subject of several reviews (69, 187, 214). The guinea pig (Cavia porcellus) had at one time been included as a member of the order Rodentia, but recent molecular phylogenetic analyses indicate that the guinea pig is actually a member of the order Caviomorpha (67). There are three common breeds of guinea pigs: the English (short-haired) breed, the Angora/Peruvian (long-haired) breed, and the Abyssinian breed, which is characterized by its so-called rosette hair pattern. Of the types used in infectious disease research, derivatives of the Dunkin-Hartley line of short-haired guinea pigs are most commonly utilized. Inbred guinea pig strains are also available, including strain 2 and strain 13 animals.

Guinea pigs have relatively lengthy gestational periods, ranging from 65 to 70 days. The average litter size is three newborn pups per pregnant animal. An aspect of guinea pig reproductive biology that makes this model particularly well suited to the study of congenital infection is the structure and histology of the guinea pig placenta. As reviewed above, the guinea pig placenta is hemomonochorial, containing a single trophoblast layer separating maternal and fetal circulations, a feature that is histologically very similar to the human placenta (127, 150). This feature of the guinea pig has enabled the exploration of the pathogenesis of a number of clinically important transplacentally acquired infections, including syphilis (282) and listeriosis (18, 19).

The guinea pig has been also been used for the evaluation of
the pathogenesis and prevention of congenital CMV infection. However, human CMV will not infect guinea pigs, so the species-specific CMV indigenous to guinea pigs, GPCMV, is employed in these studies. The history and biology of GPCMV have recently been reviewed (235). Virtually all studies of GPCMV pathogenesis appear to have been conducted with the strain originally isolated by Hartley in 1957 from infected guinea pig salivary glands, which was provided to the American Type Culture Collection (ATCC) as strain 22122 (111). Although it causes a latent, persistent infection in the salivary gland, GPCMV does not commonly cause serious disease in animals in the vivarium. However, there has been one report of two guinea pigs which were housed conventionally in separate animal facilities and had not been experimentally manipulated but were found to have evidence of disseminated CMV disease at necropsy (275).

A summary of features that make the GPCMV model valuable for the study of congenital CMV pathogenesis is included in Table 1. Like congenitally infected infants, congenitally GPCMV-infected guinea pigs exhibit a variety of forms of end-organ disease and injury, including injury to the CNS (101, 129). Importantly, infection of the cochlea, achieved either via direct inoculation or via transplacental transmission in utero, can produce SNHL, mimicking the most important complication of congenital CMV infection in infants. In one study, experimentally infected guinea pigs, inoculated with GPCMV through the round window of the cochlea, developed profound SNHL. These experimentally inoculated cochleas contained inflammatory and cytomegalic inclusion cells and showed various degrees of degenerative changes by histopathological analyses. Of interest, the number of virally infected cells was relatively small, relative to the histopathology observed. Based on this result, it was hypothesized that the histopathology might be mediated by inflammation, in addition to the cytopathic effect of the virus (129). This hypothesis was recently supported by a study of the impact of viral immune modulation genes in which a GPCMV recombinant deleted of a CC chemokine gene was found to have a reduced propensity for producing SNHL following intracochlear inoculation (237). SNHL has also been observed following congenital infection in guinea pigs. In a study of congenital GPCMV labyrinthitis, primary maternal infection in guinea pigs during the first or second trimester of pregnancy resulted in congenital infection in 64% of the offspring. Of the congenitally infected neonates, it was found that 28% had significant auditory deficits. Within the inner ear, histopathological analysis identified the presence of CMV infection localized chiefly in auditory nerve spiral ganglion cells (129). Other studies have documented that viremia in guinea pigs precedes spread of infection to the inner ear, further validating the relevance of this model to the study of CMV SNHL in infants (88). Another study of labyrinthitis following congenital transmission resulting from injection of GPCMV into 5-week-pregnant guinea pigs was recently reported (126). Immunohistochemistry detected GPCMV-infected cells in the perilymph area and spinal ganglion but not in the endolymphatic compartment or in the hair cells. These data suggested that virus spreads into the inner ear via the perilymph and neural routes in both models of direct and congenital infections.

Studies with the GPCMV model have shed light on the possible correlates of immune protection against SNHL, observations that in turn may be relevant to exploring novel interventions for infants. In experiments comparing the impact of viral inoculation on viral labyrinthitis and hearing loss in GPCMV-immune and GPCMV-naïve animals, it was shown that systemic immunity to GPCMV could protect against hearing loss following round window challenge (109). These observations were further explored in a study of immunologic and electrophysiologic responses to GPCMV inner ear infection. In that study, guinea pigs all became deaf after inoculation of GPCMV into the cochlear perilymphatic compartment, and they showed severe inflammatory changes. Animals that received inactivated virus maintained normal hearing throughout the observation period and exhibited normal cochlear morphology, indicating that viral replication was required for the effect. The effect of systemic immunity to GPCMV on inner ear viral challenge in animals was extremely significant in this study, since animals with high levels of serum antibodies to GPCMV prior to challenge demonstrated no significant hearing loss following inoculation. Seropositive animals that received live virus demonstrated a significant rise in perilymph antibody titer and showed preservation of normal cochlear morphology. Thus, in this study, systemic and inner ear immunity to GPCMV afforded protection against damage caused after direct perilymphatic viral inoculation (284). The data from these studies provide support for the hypothesis that a vaccine capable of inducing immune responses comparable to those after natural infection could hold promise in the control of CMV-induced SNHL.

Rhesus Macaque Model

Of all of the animal models of CMV pathogenesis, the RhCMV model may have the greatest relevance to the problem of congenital human CMV infection. The pathogenesis of fetal infection in this primate model is remarkably similar to that observed in human infants, and a wide range of injury in the fetus has been described, including injury to the CNS and the cochlea (154, 264). The genome organization and protein-coding content of RhCMV is very similar to those of human CMV, and the immunodominant envelope gB is a target of immune responses in naturally infected rhesus macaques (288). This observation is of particular interest in light of ongoing clinical trials of human CMV gB subunit vaccines (described below). Studies of vaccination with the gB homolog in the RhCMV model for congenital infection of macaques would potentially have great relevance to the field of human CMV vaccines.

Although the RhCMV model is uniquely well suited to the study of CMV pathogenesis and vaccines, there are practical limitations to this model. One drawback is the expense of these primates. Since congenital CMV infection in infants occurs in, at most, 2% of pregnancies and since neurodevelopmental morbidity (including SNHL) ensues in, at most, 15% of these infants (61, 66), large group sizes would be needed in a clinical trial to demonstrate the protective efficacy of vaccination. Assuming similar percentages of transmission in the RhCMV model, the costs of a definitive protection study could be prohibitive. Another challenge is the paucity of RhCMV-seronegative animals, since RhCMV infection is ubiquitous in most
colonies. These challenges support the continued development of nonprimate models of congenital CMV infection, as described below.

**Other Animal CMVs**

As noted in Table 1, a number of other animal CMVs have been described and characterized, to various degrees, in animal models of infection and disease. The chimpanzee CMV (CCMV) has recently been sequenced and has been found to have the highest degree of homology of any animal CMV to the human CMV genome (63). Unfortunately, there are no descriptions of the pathogenesis of CCMV infection, although such studies would likely be of great relevance to human health. RCMV is very well-characterized, in both its molecular biology and pathogenesis. The RCMV genome has been sequenced (278) and has proven amenable to mutagenesis strategies for generation of recombinant viruses for pathogenesis studies in rat models of disease (260). The rat model has emerged as a particularly interesting and valuable model of congenital CMV infection, and more studies are greatly needed.

**Ganciclovir**

Ganciclovir was the first compound licensed specifically for treatment of CMV infections. Ganciclovir is a synthetic acyclic nucleoside analog, structurally similar to guanine. Its structure is similar to that of acyclovir, and like acyclovir, it requires phosphorylation for antiviral activity. The enzyme responsible for phosphorylation of GCV is the product of the CMV UL97 gene, a protein kinase and phosphotransferase (102, 153, 262). Following phosphorylation by UL97, the cellular enzymes phosphorylate the monophosphate form to the di- and triphosphate metabolites; the ganciclovir triphosphate metabolite exerts the antiviral effect in the CMV-infected cell.

Ganciclovir is the treatment of choice for severe CMV disease in immunocompromised adult patients (i.e., bone marrow/solid organ transplant recipients and HIV-infected individuals with CMV end-organ disease). For congenital and perinatal CMV infections, the role of ganciclovir is less well established, although recent evidence suggests that it is of

**Antiviral Drugs**

The currently licensed antivirals for CMV therapy share the feature of inhibition of the viral DNA polymerase, although they differ in their pharmacology, and they are summarized in Table 2. There is limited information about the ability of antiviral therapy to limit the neuropathogenesis of congenital CMV infection, and more studies are greatly needed.

**TABLE 2. CMV antivirals in clinical usage**

<table>
<thead>
<tr>
<th>Antiviral agent</th>
<th>Mechanism of action</th>
<th>Dose</th>
<th>Clinical use</th>
<th>Major toxicities</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ganciclovir</td>
<td>Inhibition of CMV DNA polymerase; requires phosphorylation by virus-specific kinase (UL97 protein)</td>
<td>10–12 mg/kg/day (intravenously) divided twice daily</td>
<td>CMV retinitis; end-organ disease in immune-compromised patients; congenital infection</td>
<td>Neutropenia, thrombocytopenia; animal studies suggestive of theoretical risks of teratogenicity and inhibition of spermatogenesis</td>
<td>Efficacy against CMV-associated hearing loss in the setting of congenital infection</td>
</tr>
<tr>
<td>Valganclovir</td>
<td>Prodrug (valine ester) of ganciclovir; metabolized to ganciclovir following oral dosage</td>
<td>900 mg (orally) twice daily (for active CMV disease)</td>
<td>CMV retinitis; preemptive therapy in transplant patients</td>
<td>Neutropenia, thrombocytopenia</td>
<td>Orally bioavailable; optimal oral dose for children not established</td>
</tr>
<tr>
<td>Foscarnet</td>
<td>Inhibition of CMV DNA polymerase; does not require phosphorylation</td>
<td>180 mg/kg/day (intravenously) in 2–3 divided doses</td>
<td>CMV retinitis, end-organ disease; ganciclovir resistance</td>
<td>Nephrotoxicity; toxicity to developing bones/teeth</td>
<td>Prehydration minimizes renal toxicity</td>
</tr>
<tr>
<td>Cidofovir</td>
<td>Inhibition of DNA polymerase; does not require phosphorylation</td>
<td>5 mg/kg (intravenously) once weekly for two wk, then biweekly</td>
<td>CMV end-organ disease in immune-compromised patients; ganciclovir resistance</td>
<td>Renal toxicity</td>
<td>Pretreatment with probenecid, prehydration reduces renal toxicity</td>
</tr>
<tr>
<td>CMV immune globulin</td>
<td>Uncertain; presumed to be due to direct neutralization of viral infectivity by Ig and/or improvement in antibody avidity</td>
<td>50–150 mg/kg (intravenously) per schedule (transplant patients); 100–200 U/kg (pregnant patients)</td>
<td>Prophylaxis against CMV (transplant patients); possible value for prevention of transplacental transmission of CMV in pregnancy</td>
<td>Headache; fever and chills; facial flushing; use with caution in patients with IgA deficiency</td>
<td>Efficacy for prevention of fetal CMV infection unknown; randomized trials for congenital infection ongoing</td>
</tr>
</tbody>
</table>

Neutropenia, thrombocytopenia; animal studies suggestive of theoretical risks of teratogenicity and inhibition of spermatogenesis

Neutropenia, thrombocytopenia

Nephrotoxicity; toxicity to developing bones/teeth

Renal toxicity

Pretreatment with probenecid, prehydration reduces renal toxicity

Headache; fever and chills; facial flushing; use with caution in patients with IgA deficiency

Efficacy for prevention of fetal CMV infection unknown; randomized trials for congenital infection ongoing

Neutropenia, thrombocytopenia; animal studies suggestive of theoretical risks of teratogenicity and inhibition of spermatogenesis

Neutropenia, thrombocytopenia

Nephrotoxicity; toxicity to developing bones/teeth

Renal toxicity

Pretreatment with probenecid, prehydration reduces renal toxicity

Headache; fever and chills; facial flushing; use with caution in patients with IgA deficiency

Efficacy for prevention of fetal CMV infection unknown; randomized trials for congenital infection ongoing

Neutropenia, thrombocytopenia; animal studies suggestive of theoretical risks of teratogenicity and inhibition of spermatogenesis

Neutropenia, thrombocytopenia

Nephrotoxicity; toxicity to developing bones/teeth

Renal toxicity

Pretreatment with probenecid, prehydration reduces renal toxicity

Headache; fever and chills; facial flushing; use with caution in patients with IgA deficiency

Efficacy for prevention of fetal CMV infection unknown; randomized trials for congenital infection ongoing
value in ameliorating some of the disabilities seen in these infants. The first reports of the use of ganciclovir therapy for congenital CMV infection date to the late 1980s (75, 206). In subsequent reports (16, 60, 76, 117, 124, 175, 185, 186, 220, 272), ganciclovir has been shown to be generally safe and well tolerated when used in newborns and has appeared to be useful in the management of severe, focal end-organ disease (pneumonitis, hepatitis, etc.) in infants. Based on these reports, the use of ganciclovir is generally indicated in the short-term management of any infant with severe or symptomatic CMV disease, including viremia. It is important to note that no sustained effect on CMV shedding at mucosal sites can be expected; once therapy is completed, infants resume excreting CMV in urine and saliva cultures. Although ganciclovir appears to be valuable for short-term management of CMV infection in infants in some settings, it has been less clear whether use of ganciclovir provides any long-term benefit for congenital or perinatally acquired CMV infection. Recently, the results of a phase III randomized double-blind study of parenteral ganciclovir in neonates with symptomatic congenital CMV infection have been reported (134). This study was not a placebo-controlled trial, because of the ethical concerns regarding the prolonged intravenous administration of a placebo through a central venous catheter. Enrollment took place at participating Collaborative Antiviral Study Group sites over a period of nearly 10 years. The primary study end point was an improved brain stem-evoked response (BSER) between baseline and 6-month follow-up or, for those infants with normal hearing at enrollment, maintenance of normal hearing between baseline and 6-month follow-up. Of the 100 patients enrolled in the study, 42 patients had both baseline and 6-month follow-up BSER audiometric examinations. Twenty-one (84%) of 25 ganciclovir recipients either had improved hearing or maintained normal hearing between baseline and 6 months. In contrast, only 10 (59%) of 17 control patients had improved or stable hearing (P = 0.06). Results were even more encouraging when the study and control groups were compared for subsequent maintenance of normal hearing. None (0%) of 25 ganciclovir recipients had worsening of hearing between baseline and 6 month follow-up, compared to 7 (41%) of 17 control patients (P < 0.01). The study further examined whether there was a therapeutic benefit after 12 months of follow-up. Among 43 patients who had a BSER both at baseline and at 1 year or beyond, five (21%) of 24 ganciclovir recipients had worsening of hearing, versus 13 (68%) of 19 control patients (P < 0.01).

Since ganciclovir is associated with a number of drug toxicities (particularly myelosuppression), its use in newborns and infants requires careful consideration. Ganciclovir penetrates well into the CNS (133), an observation of importance for treatment strategies for newborns designed to provide protection against CMV-induced neurodevelopmental injury.

Valganciclovir. Valganciclovir is the valine ester of ganciclovir. In contrast to oral formulations of ganciclovir, valganciclovir is very well absorbed following oral administration. It is rapidly metabolized into ganciclovir following oral dosing. Valganciclovir is indicated for therapy of CMV retinitis in HIV-positive patients and for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk for CMV disease (donor CMV seropositive/recipient CMV seronegative). The side effect profile is similar to that of ganciclovir. The commercially available formulation is produced as a tablet; however, there is a suspension formulation available for investigational use (133). There is currently little experience with the use of this agent in infants and children, but the convenience of oral dosage makes this agent attractive for future clinical trial evaluation in the setting of perinatally acquired CMV infection.

Foscarnet. Foscarnet, an inorganic pyrophosphate analog, is a second-line treatment for CMV infection. The mechanism of action of foscarnet, which is similar to ganciclovir’s, is inhibition of the CMV DNA polymerase. However, in contrast to ganciclovir, foscarnet does not require phosphorylation for antiviral activity. The drug directly blocks the pyrophosphate binding site of the DNA polymerase. Resistance to foscarnet may emerge on therapy. Mutations in the CMV UL54 (DNA polymerase) gene which confer resistance to foscarnet have been described (58). Foscarnet has a significant risk of producing nephrotoxicity. Foscarnet has an important toxicity relevant to pediatric practice, which is its ability to affect bone and tooth development, necessitating caution when it is used in children or pregnant women. In contrast to ganciclovir, the risks of myelosuppression with foscarnet are minimal, and this agent is the recommended CMV therapy for patients with bone marrow failure. Although consideration should be given to the use of foscarnet in a setting of known or suspected ganciclovir resistance, there are very few data on the use of this agent in newborns or young infants, precluding definitive dosage recommendations in this setting.

Cidofovir. Another second-line therapy for CMV disease, cidofovir, is, like foscarnet, an inhibitor of the CMV DNA polymerase. Cidofovir is an acyclic phosphonate nucleoside analog, which already has a single phosphate group attached in the formulation used for clinical administration. Hence, it does not require or utilize an initial viral (UL97-mediated) phosphorylation for antiviral activity, but it does undergo additional phosphorylation by cellular kinases to its active form. In its fully phosphorylated form, cidofovir is selectively incorporated into the viral DNA chain, inhibiting viral DNA synthesis. Cidofovir is eliminated by renal clearance, although the drug persists in cells for prolonged periods, and its metabolites have very long intracellular half-lives, which allows for an intermittent dosage schedule. Unfortunately, cidofovir has a wide range of significant toxicities, including nephrotoxicity, neutropenia, and metabolic acidosis. In animal studies, cidofovir is carcinogenic and teratogenic, and it may be associated with gonadal injury in males. Prehydration with saline and treatment with probenecid prior to the infusion are recommended to attempt to prevent the problem of nephrotoxicity. There is no information available about the use of cidofovir in neonates with CMV infection, making dose recommendations in this setting uncertain.

CMV Immune Globulin

CMV immune globulin is a pooled, high-titer intravenous Ig preparation prepared from donors with high titers of CMV antibodies. The presumed mechanism is neutralization of virus infectivity, via interactions with viral envelope glycoproteins. CMV immune globulin is indicated, either alone or in combi-
Vaccines evaluated in clinical trials

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human CMV-specific antibody responses; no clinical trials active or anticipated</td>
<td>AD169 vaccine</td>
</tr>
<tr>
<td>Elicits humoral and cellular immune responses; reduced human CMV disease in renal transplant recipients; phase I studies with coadministered recombinant IL-12</td>
<td>Towne vaccine</td>
</tr>
<tr>
<td>Good safety profile; attenuated compared to Toledo strain; no efficacy data available</td>
<td>Towne/Toledo &quot;chimeric&quot; vaccine</td>
</tr>
</tbody>
</table>

Subunit vaccines

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutralizing antibody- and cell-mediated responses; efficacy studies ongoing in phase II/III trials</td>
<td>gB/MB59 adjuvant</td>
</tr>
<tr>
<td>Suboptimal immunogenicity; prime-boost when administered with Towne vaccine</td>
<td>gB/canarypox-vectored vaccine</td>
</tr>
<tr>
<td>Good safety profile; antibody- and cell-mediated immune responses</td>
<td>pp65 (UL83)/canarypox-vectored vaccine</td>
</tr>
<tr>
<td>DNA adjuvanted with poloxamer/benzalkonium chloride</td>
<td>gB/pp65/IIE1 trivalent DNA vaccine</td>
</tr>
<tr>
<td>Phase II studies ongoing in hematopoietic stem cell transplant recipients</td>
<td>gB/pp65 bivalent DNA vaccine</td>
</tr>
<tr>
<td>Replication-deficient VRPs; phase I clinical trial recently initiated</td>
<td>gB/pp65/IIE1 alphavirus replicon vaccine</td>
</tr>
</tbody>
</table>

Preclinical vaccine approaches

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major glycoprotein constituent of virion; majority of human sera contain anti-ggII antibodies</td>
<td>gM/gN (ggII complex)</td>
</tr>
<tr>
<td>Target of neutralizing antibody responses; protective in murine CMV model</td>
<td>gH/gI/gO (ggIII complex)</td>
</tr>
<tr>
<td>DNA polymerase (UL54) and helicase (UL105); protective in murine model</td>
<td>Nonstructural genes/novel CTL targets</td>
</tr>
<tr>
<td>Prime with cocktail of plasmid DNA vaccines; boost with formalin-inactivated viral particles; induces &quot;sterilizing immunity&quot; in murine model</td>
<td>Prime-boost strategy</td>
</tr>
<tr>
<td>Protective in murine and guinea pig models</td>
<td>Bacterial artificial chromosomes</td>
</tr>
<tr>
<td>Effective in murine model; &quot;polyepitope&quot; vaccine approach; requires knowledge of HLA status</td>
<td>Peptide vaccines</td>
</tr>
<tr>
<td>Noninfectious particles; highly immunogenic in animal models; humoral and cell-mediated immune responses</td>
<td>Dense body vaccines</td>
</tr>
</tbody>
</table>

TABLE 3. Candidate CMV vaccines

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Replication-deficient VRPs; phase I clinical trial recently initiated</td>
<td>AD169 vaccine</td>
</tr>
<tr>
<td>Human CMV-specific antibody responses; no clinical trials active or anticipated</td>
<td>AD169 vaccine</td>
</tr>
<tr>
<td>Good safety profile; antibody- and cell-mediated immune responses</td>
<td>AD169 vaccine</td>
</tr>
<tr>
<td>Protective in murine and guinea pig models</td>
<td>AD169 vaccine</td>
</tr>
<tr>
<td>Effective in murine model; &quot;polyepitope&quot; vaccine approach; requires knowledge of HLA status</td>
<td>AD169 vaccine</td>
</tr>
<tr>
<td>Noninfectious particles; highly immunogenic in animal models; humoral and cell-mediated immune responses</td>
<td>AD169 vaccine</td>
</tr>
</tbody>
</table>

A number of candidate CMV vaccines have been evaluated in clinical trials. These vaccine candidates are summarized in Table 3. A wide variety of expression strategies have been employed for CMV vaccines, but generally these vaccines can be conceptually subdivided into the categories of live, attenuated vaccines and subunit vaccines that target individual CMV proteins. Ongoing progress in the study of these vaccines is briefly considered below.

**Vaccines**

A number of candidate CMV vaccines have been evaluated in clinical trials. These vaccine candidates are summarized in Table 3. A wide variety of expression strategies have been employed for CMV vaccines, but generally these vaccines can be conceptually subdivided into the categories of live, attenuated vaccines and subunit vaccines that target individual CMV proteins. Ongoing progress in the study of these vaccines is briefly considered below.

**Live, attenuated CMV vaccines.** The first live CMV vaccine candidate tested in humans was a laboratory-adapted vaccine based on the attenuated AD169 (179) strain of the virus. Subsequent trials with another live, attenuated vaccine, the Towne strain, confirmed that that this vaccine approach could elicit neutralizing antibodies as well as CMV-specific cell-mediated immune responses, including CD8+ cytotoxic T-lymphocyte
(CTL) responses, in immunocompetent individuals (4, 8, 79, 92, 99, 144, 205, 215, 257). The efficacy of Towne vaccine was tested in several studies with kidney transplant recipients (patients at high risk for development of CMV disease), and although the vaccine failed to prevent CMV infection following transplantation, vaccination did provide a favorable, protective impact on severe CMV disease (20, 203, 204, 227). However, a placebo-controlled study of Towne vaccine in seronegative mothers who had children attending group day care indicated that immunization failed to protect these women from CMV infection. Since the lack of efficacy of Towne vaccine may be due to overattenuation of the virus relative to clinical isolates of CMV, a recent vaccine study using "chimeric" vaccines, in which large regions from the genome of the unattenuated Toledo strain of CMV were substituted for the corresponding regions of the Towne genome, was performed (131). Four independent chimeric vaccines were evaluated in a recently completed double-blinded, placebo-controlled phase I trial (113, 234). All of the vaccines were found to be well tolerated, justifying further evaluation of these vaccines in seronegative subjects.

**Subunit CMV vaccines.** The leading subunit CMV vaccine candidate is the immunodominant envelope glycoprotein, gB (the UL55 gene product), based on the ability of this protein to elicit high-titer, virus-neutralizing antibody responses in the setting of natural CMV infection. Other viral proteins actively being evaluated as subunit vaccine candidates include the tegument phosphoprotein, pp65 (the UL83 gene product), and IE1 (the UL123 gene product), both of which elicit T-cell responses. The current status of individual subunit vaccine candidates is summarized below (Table 3).

(i) **Adjuvanted protein vaccines.** The formulation of CMV gB currently being utilized in clinical vaccine trials is a recombinant protein expressed in Chinese hamster ovary (CHO) cells (250, 251). In a phase I randomized, double-blind, placebo-controlled trial in adults, gB vaccine, combined either with a novel adjuvant, MF59, or alum adjuvant, elicited levels of virus-neutralizing antibody that exceeded those observed in CMV-seropositive control subjects (197). In all subsequent studies to date (86, 176), the safety profile of the vaccine has been very favorable, with injection site discomfort being the only significant adverse event observed. There is currently a phase III efficacy study of gB/MF59 vaccine ongoing in young, CMV-seronegative women who are vaccinated postpartum (289). These women are at high risk for primary CMV infection following delivery. Since these women commonly become pregnant again soon after delivery, this study will be of great importance to the prevention of congenital CMV infection in subsequent deliveries.

(ii) **DNA vaccines.** DNA vaccines developed for CMV (265) have focused on the gB, IE1, and pp65 genes as the candidate target immunogens. There are currently phase I clinical trials under way of both a bivalent CMV DNA vaccine candidate, using plasmid DNA encoding pp65 and gB, and a trivalent vaccine candidate, which also includes a third plasmid encoding the IE1 gene product, developed and produced by Vical Vaccines (240, 277). The vaccines are formulated using the poloxamer adjuvant CRL1005 and benzalkonium chloride. A study is currently ongoing with the bivalent DNA vaccine in a hematopoietic stem cell transplant population. Both donors and recipients are being vaccinated, with the goal of reducing CMV disease, viral load, and use of antiviral therapies in the posttransplant period. The long-term role of these vaccines for potential control of congenital CMV infection in women of child-bearing age remains to be determined, as does the ultimate acceptability of DNA vaccines for clinical use.

(iii) **Vectored vaccines.** Another approach to CMV subunit vaccination is utilization of a “vectored” vaccine, in which the gene product of interest is expressed in the context of a non-replicating (usually viral) vector. Once example of such a vaccine vector is a canarypox vector known as ALVAC, an attenuated poxvirus that replicates productively in avian species but abortively in mammalian cells. ALVAC expressing CMV gB has been studied in several clinical trials (7, 30). An ALVAC vaccine expressing pp65, the major CTL target in naturally CMV seropositive persons, has also been evaluated in human trials. The ALVAC expression vector has been found to be safe and well tolerated, although the expression strategy does not appear to offer advantages in immunogenicity compared to other approaches. Other vectored CMV vaccine expression strategies include an approach based on the modified vaccinia virus Ankara (279) and a Venezuelan equine encephalitis virus-vectored CMV vaccine (235), manufactured by AlphaVax Vaccines. Both approaches show promise, and the Venezuelan equine encephalitis virus-vectored approach provided protection in an animal model of congenital CMV infection (see below), but these vaccines have not yet been tested in human clinical trials.

**Preclinical vaccine approaches.** Other vaccine approaches have been suggested for development of a CMV vaccine, and these are the subject of a recent review (226). These potential strategies are listed in Table 3. CMV glycoproteins other than gB have been considered for vaccine development, including the gCII complex, consisting of gN (UL73) and gM (UL100), and the gCIII complex, consisting of gH (UL75), gO (UL74), and gL (UL115). Vaccines based on nonstructural proteins that are highly conserved among the CMVs, including the DNA polymerase and helicase genes, show promise in murine models. Dense bodies, which are enveloped, replication-defective particles formed during replication of CMVs in cell culture, are capable of inducing virus-neutralizing antibodies and T-cell responses after immunization of mice (226). The use of synthetic peptides comprising immunodominant cytotoxic T-cell epitopes has been advocated, although such vaccines would have to be tailored for donor-recipient pairs based on HLA genetics. Viral genomes cloned in Escherichia coli as bacterial artificial chromosomes provide the opportunity to generate recombinant, “designer” vaccines with specific genomic deletions or insertions that could modify the immune response or improve the safety profile of the candidate vaccine. A “prime-boost” approach, in which priming with DNA vaccination is followed by boosting with formalin-inactivated viral particles, elicits high levels of neutralizing antibodies as well as CD8+ T-cell responses. These approaches deserve further attention in preclinical study and in phase I clinical trials. The importance of identifying the maternal immune factors that protect the developing
fetal CNS cannot be overstated, and this should be a key priority in future vaccine design.

Validation of vaccines for congenital CMV in animal models. Prioritization of vaccine candidates for clinical trials can be based on results identified in the guinea pig model of congenital CMV infection. In light of the ability of GPCMV to cross the placenta and infect the pup in utero, the guinea pig provides an ideal small animal model for the study of vaccines designed to protect the fetus. A live, attenuated GPCMV vaccine, as well as a partially purified, soluble envelope vaccine, administered with Freund’s adjuvant, was able to show protection against acute viremia and death and to reduce the incidence and extent of maternal and fetal infection (31). Adjuvanted glycoprotein vaccines, generated by immunoaffinity purification, have also been shown to protect newborn pups against congenital infection and disease (40, 110). Molecular cloning techniques allowed extension of these studies to generation of cloned, recombinant subunit vaccine candidates in a number of expression systems. Subunit vaccines based on the GPCMV homolog of gB are capable of inducing neutralizing antibody responses when administered either as DNA vaccines or as adjuvanted, purified glycoprotein vaccines expressed in baculovirus (231, 232). Efficacy analyses against congenital GPCMV have been performed with these vaccines. A DNA gB subunit vaccine was able to reduce congenital infection rates following third-trimester challenge of vaccinated, pregnant guinea pigs. In a group of 26 live-born pups in the control group, the total congenital infection rate was 77% (20/26). In contrast, in the gB-vaccinated group the total congenital infection rate was 41% (11/27) ($P < 0.05$ versus control group). This was the first study indicating that a DNA vaccine was capable of providing protection against congenital CMV infection (231), and these data provide support for the ongoing development and testing of DNA vaccines for clinical trials. A three-dose series of purified, recombinant gB, expressed and purified from baculovirus, was studied following administration with either Freund’s adjuvant or alum-based adjuvant (233). Among 36 live-born pups in the Freund’s adjuvant group, 8 (22%) had congenital GPCMV infection, compared to 15/32 pups (47%) with in the alum adjuvant group ($P < 0.05$ versus Freund’s adjuvant). The basis for the improved protection in the Freund’s adjuvant group was the induction of higher virus-neutralizing antibody titers, an observation that may be relevant to clinical trials of gB vaccine.

Recently, the UL83 (pp65) homolog of CMV, GP83, was also evaluated as a vaccine against congenital CMV infection and disease in the guinea pig model. This vaccine was developed from a propagation-defective, single-cycle RNA replicon vector system, based on an attenuated strain of the alphavirus Venezuelan equine encephalitis virus. This expression system was used to produce virus-like replicon particles (VRPs) expressing GP83. Subsequent vaccination with VRP-GP83 induced antibodies and CD4$^+$ and CD8$^+$ T-cell responses in GPCMV-seronegative female guinea pigs. Guinea pigs immunized with VRP-GP83 vaccine were bred for pregnancy and subsequent GPCMV challenge during the early third trimester. Dams vaccinated with VRP-GP83 had improved pregnancy outcomes compared with controls, supporting the concept that T-cell-mediated immune responses directed against a CMV matrix protein can protect against congenital CMV infection and disease.

Although these studies shed light on mechanisms that protect the fetus, there is a paucity of information about how vaccination in animal models can protect against neuropathogenesis. This is a high-priority area for future research in the guinea pig model. Assessments of vaccine-mediated protection against SHNL and neuropathology in this and other congenital infection models will be of great importance in clarifying which human CMV vaccines strategies should be emphasized in clinical trials. An important issue to clarify in future clinical trials will be the impact of reinfection in women with preconception immunity on the incidence and morbidity of congenital CMV infection. A fundamental and unresolved quandary is that if vaccines induce immunity but preexisting natural immunity does not fully protect women from CMV reinfection and the fetal consequences of these infections, could vaccines ever be effective in eradication of congenital CMV disease? The answer may lie in how the vaccine would be applied in clinical practice. As suggested by some authorities, the force of infection of CMV is low, and a universal immunization program could eliminate CMV infection from a community, even if the vaccine was only modestly effective (103) Thus, the issue may be not the immunogenicity of the vaccine but the degree to which CMV vaccination could confer herd immunity. If herd immunity in turn decreases the prevalence of CMV infection in the population, then the incidence of congenital CMV infection would be predicted to be substantially reduced. This was the effect observed following adoption of universal immunization against rubella (103), which led to the virtual elimination of congenital rubella syndrome.

SUMMARY AND PERSPECTIVES

Congenital CMV infection is the predominant cause of developmental neurological disabilities in the United States. It most frequently begins as a primary infection in the pregnant mother, who may be exposed to several risk factors, including her own CMV-infected children who shed infectious virus. Prior exposure to CMV markedly reduces the possibility of fetal infection but does not preclude the virus from crossing the placenta to infect the fetus. Not only does the infected placenta serve as an amplifying reservoir, but CMV infection may also cause placental insufficiency that result in fetal pathologies. Gestational age at infection greatly influences neurological outcomes in the fetus. However, the combination of factors that render the developing brain susceptible to CMV infection is poorly understood.

CMV infection of the fetus may alter the “normal blueprint” of the developing brain, thus resulting in long-term neurological sequelae. Studies that investigate mechanisms that alter developmental paradigms will help elucidate CMV neuropathogenesis and explain the clinical outcomes of congenital CMV infection. Neural stem cells in the fetal brain appear to be the predominant cell type affected during development by CMV. There is an abundance of neural stem cells in the fetal brain, and their increased susceptibility to viral infection explains the predominance of neurological sequelae associated with congenital CMV infection. Some possible mechanisms of
Developmental disruption due to CMV infection include (i) the loss of neural stem cells or intermediate progenitors, the building blocks of the developing brain, which are involved in the development of new neural circuits in both the developing and adult brain. These cells divide symmetrically, to renew the stem cell pool, or asymmetrically, to differentiate into new brain cells (astrocytes, oligodendrocytes, and neurons), either directly or via an intermediate transitional progenitor cell (red cells). The development path for new neural circuitry involves the migration of the early neuronal precursor, neuroblasts (green cells), through a directed path that is supported in part by astroglial cells. CMV brain infection may potentially affect any or all of these stages of development and influence the neurological outcomes of congenital infection. This schematic depicts potential mechanisms by which formation of new neural circuits in the developing brain may be affected by CMV infection. 1. Infection of neural stem cells may disrupt their ability to maintain a self-renewing cycle that would influence subsequent processes involved in brain development. 2. Differentiation of neural stem cells via the transitional cells and eventually neuroblasts may also be disrupted by CMV infection, potentially skewing their end-differentiated fate. 3. It has also been shown that brain infection affects the migratory patterns of neuroblasts, particularly during cortical and cerebellar development, which may involve inhibition of migration to distal brain structures. 4. This might alter the migratory patterning of specific brain structures, such as by causing improper layering of the neocortex. 5. Since glial cells are also susceptible to CMV infection, demonstrated both in vivo and in vitro, one could postulate that important functions of glia in directing neuronal layering patterns may be affected. 6. Finally, CMV infection can induce a myriad of inflammatory mediators, including cytokines, oxidative radicals, and other neurotoxic chemicals. These mediators may potentially affect the immature neuron by directly inducing cytotoxicity or may affect neuronal function by altering the microenvironment that alters normal brain cell physiology. In addition, immune-mediated clearance of infected cells may have an impact on the cellular milieu. Many of these concepts are still speculative, and more research is required to elucidate the neuropathogenesis of CMV infection.

Antiviral drugs are available for treatment of congenital CMV infection, and there is evidence that therapy ameliorates the severity of one of the CNS complications of infection, SNHL. Long-term neurodevelopmental follow-up studies should further clarify the value of antiviral therapy in congenitally infected infants. Uncontrolled studies of therapy in utero with CMV immune globulin have suggested an impact on neuropathogenesis, and controlled trials should be conducted with pregnant women. Finally, CMV vaccines may hold the greatest promise in reducing the neurodevelopmental consequences of congenital infection, although the immune correlates of protection of the fetus remain incompletely defined. Preclinical study with relevant animal models may provide insights into strategies that bear further testing in human clinical trials.
Until more-effective interventions are available, better education of women of child-bearing age will be important. Only with increased public awareness of the urgency of this problem can the societal and political forces necessary to effect changes be marshaled. These changes include increased funding for the study of the pathogenesis of congenital CMV and an increased sense of urgency in conducting clinical vaccine trials. Web-based information from both the Centers for Disease Control (http://www.cdc.gov/cmv/) and parent support groups founded by individuals who have children afflicted with congenital CMV (http://www.cmfwfoundation.org) can be an effective conduit of knowledge and perspective that help to increase public awareness of this urgent problem.

ACKNOWLEDGMENTS

This work was supported by NIH grants N0308836, HD038416, and HD044864.

REFERENCES

212. Pulliam, L.


238. Schupfer, P. C., J. R. Murph, and J. F. Bale, Jr. 1986. Survival of cytomeg- 


246. pathol. 98:590–596.


250. productive infection by endothelial-cell-activated human cytomegalovi-

251. rus strains and present viral IE1 protein to CD+ T cells despite late 


270. ulated gene expression and is attenuated by infection in the developing brain. J. Virol. 81:332–348.


277. cine: evaluation of plasmid DNA biodistribution/perse and integra- 


